These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 28392154

  • 1. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
    Ezz El Din M.
    Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
    [Abstract] [Full Text] [Related]

  • 2. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ, Tian J, Chen X, Wang D, Li CL.
    Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
    Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E.
    J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
    [Abstract] [Full Text] [Related]

  • 4. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
    Kondo T, Takagi T, Kobayashi H, Iizuka J, Nozaki T, Hashimoto Y, Ikezawa E, Yoshida K, Omae K, Tanabe K.
    Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.
    Cancer; 2012 Mar 01; 118(5):1252-9. PubMed ID: 21898376
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, Rini BI.
    Eur J Cancer; 2014 Apr 01; 50(6):1084-9. PubMed ID: 24559686
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
    Miyake H, Harada K, Miyazaki A, Fujisawa M.
    Med Oncol; 2015 Mar 01; 32(3):78. PubMed ID: 25698532
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.
    J Clin Oncol; 2009 Sep 01; 27(25):4068-75. PubMed ID: 19652072
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
    Iwamoto K, Ishihara H, Takagi T, Kondo T, Yoshida K, Iizuka J, Tanabe K.
    Med Oncol; 2018 Apr 23; 35(6):78. PubMed ID: 29687160
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
    Makino K, Yoda K, Tomoishi J, Kume H.
    BMC Res Notes; 2014 Dec 04; 7():872. PubMed ID: 25471941
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry.
    Boegemann M, Hubbe M, Thomaidou D, Blackburn S, Bent-Ennakhil N, Wood R, Bargo D.
    Anticancer Res; 2018 Nov 04; 38(11):6413-6422. PubMed ID: 30396966
    [Abstract] [Full Text] [Related]

  • 19. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
    Guida FM, Santoni M, Conti A, Burattini L, Savini A, Zeppola T, Caricato M, Cascinu S, Tonini G, Santini D.
    Crit Rev Oncol Hematol; 2014 Dec 04; 92(3):208-17. PubMed ID: 25151214
    [Abstract] [Full Text] [Related]

  • 20. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH, Park I, Lee JL.
    Cancer Chemother Pharmacol; 2016 Aug 04; 78(2):325-32. PubMed ID: 27324136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.